Lymphoproliferative disorders News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

FDA Puts Clinical Holds on Trials of BPX-501 - OncLive



OncLive
 
FDA Puts Clinical Holds on Trials of BPX-501 
OncLive
Children in the study had acute leukemia (n = 53), primary immune deficiencies (n = 26), erythroid disorders (n = 17), Fanconi anemia (n = 7), and other diseases (n = 9). All patients were transplanted after depletion of donor alpha/beta T cells and ...

and more » 


Evolving Recognition of Chronic Hepatitis C Infection as a Modifiable Risk Factor for CVD - Infectious Disease Advisor



Infectious Disease Advisor
 
Evolving Recognition of Chronic Hepatitis C Infection as a Modifiable Risk Factor for CVD 
Infectious Disease Advisor
Chronic hepatitis C (CHC) infection has a worldwide prevalence of 2.5% and is the leading cause of death from liver cirrhosis globally. Morbidity and mortality are not, however, restricted to the effects of chronic infection on the liver. Many studies ...

 


Current Approaches to Diagnosis and Risk Stratification in CLL - Targeted Oncology



Targeted Oncology
 
Current Approaches to Diagnosis and Risk Stratification in CLL 
Targeted Oncology
Flow cytometric analysis for these markers is therefore used to establish a differential diagnosis from other B-cell lymphoproliferative disorders such as marginal zone lymphoma, lymphoplasmacytic lymphoma, and mantle cell lymphoma (MCL), all of which ...

and more » 


Physiopathogenesis of Hematological Cancer ? Healthcare, Healthcare Services Industries - MilTech



Physiopathogenesis of Hematological Cancer ? Healthcare, Healthcare Services Industries 
MilTech
It provides updated in 2018 year analysis of industries from Healthcare, Healthcare Services Markets. The number of new discoveries related to diagnostics and therapeutics of hematological cancer is significant. These have resulted in continuous ...

and more » 


The Diagnosis of Lymphoproliferative Diseases. 2nd Edition ... - satPRnews (press release)



satPRnews (press release)
 
The Diagnosis of Lymphoproliferative Diseases. 2nd Edition ... 
satPRnews (press release)
The The Diagnosis of Lymphoproliferative Diseases. 2nd Edition Report has been published. It provides updated in 2018 year analysis of industries from Healthcare, Healthcare Services Markets. This highly illustrated, diagnostic guidebook provides a ...

and more » 


Atara Biotherapeutics: What The FDA Acceptance Of The Two Phase 3 Trials Initiation Entails - Seeking Alpha



Atara Biotherapeutics: What The FDA Acceptance Of The Two Phase 3 Trials Initiation Entails 
Seeking Alpha
The FDA cleared Atara to commence two phase 3 studies (MATCH and ALLELE) for its CAR-T (ATA-129) in patients with rituximab-refractory EBV associated post-transplant lymphoproliferative disorders. Outcomes and EU conditional marketing authorization are ...

 


Cancer after heart transplant common, confers mortality risk - Healio



Cancer after heart transplant common, confers mortality risk 
Healio
Outcomes of interest included incidence of, types of and time to de novo malignancy. Patients were stratified by whether they received their transplant between 2000 and 2005 or between 2006 and 2011. The risk for any de novo solid malignancy was 10.7 ...

 


Primary Central Nervous System Lymphoma?PART 1: Epidemiology, Diagnosis, Staging, and Prognosis - Cancer Network



Cancer Network
 
Primary Central Nervous System Lymphoma?PART 1: Epidemiology, Diagnosis, Staging, and Prognosis 
Cancer Network
[7] These are classified as a distinct entity?posttransplant lymphoproliferative disorders?and can follow a natural history similar to that of typical primary CNS lymphoma or may follow a more indolent course. The risk for development of ...

 


ATARA Biotherapeutics (ATRA) Announces Two Presentations at ASH - StreetInsider.com



ATARA Biotherapeutics (ATRA) Announces Two Presentations at ASH 
StreetInsider.com
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here. Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf T-cell immunotherapy company developing novel treatments for patients ...

and more » 


Current Approaches to Diagnosis and Risk Stratification in Chronic ... - Targeted Oncology



Targeted Oncology
 
Current Approaches to Diagnosis and Risk Stratification in Chronic ... 
Targeted Oncology
Chronic lymphocytic leukemia (CLL) is a malignancy characterized by the clonal proliferation and accumulation of small, mature-appearing CD5-positive B lymphocytes in the blood, bone marrow, and secondary lymphoid tissues.1 A CLL diagnosis is ...

and more »